NMD Pharma has secured clearance for an Investigational New Drug (IND) application from the US Food and Drug Administration to commence a Phase IIb clinical trial of muscle-targeted therapy, NMD670, for generalised myasthenia gravis (gMG).
This study will have gMG patients who are positive for anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibodies.
Go deeper with GlobalData
The dose range-finding, double-blind, placebo-controlled trial will assess the twice-a-day dose of NMD670 in gMG patients.
To be conducted at both US and European study centres, the trial will commence subject enrolment soon.
A muscle-targeted small molecule inhibitor specifically targeting the ClC-1 chloride ion channel in skeletal muscles, NMD670 is being developed to alleviate persistent or fluctuating symptoms in gMG patients who are not fully responsive to existing standard treatments.
See Also:
Recent Phase I/IIa trial results have shown promising clinical proof-of-mechanism for ClC-1 inhibitors in gMG patients, along with a strong safety and tolerability profile for NMD670.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataNMD Pharma announced in November last year that it secured approximately $80m in a Series B financing round.
These funds are earmarked to complete three Phase II studies of NMD670, including trials for gMG, spinal muscular atrophy, and Charcot-Marie-Tooth disease.
NMD Pharma CEO Thomas Holm Pedersen said: “This is an important milestone for NMD Pharma, enabling us to progress our lead development candidate NMD670 into a Phase IIb trial in the US in generalised myasthenia gravis patients with AChR and MuSK positive antibodies.
“It follows positive Phase I/IIa data which provided proof-of-mechanism and where clinically and statistically significant effects were seen in patients.
“We are excited to bring forward a unique and validated muscle-targeted approach with promise to provide improvements in muscle function leading to clinically meaningful improvements in activities of daily living and quality of life.”
